- Home
- ADSE vs LXRX Comparison
ADSE vs LXRX Comparison
Compare ADSE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | LXRX |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 900.0M | 996.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ADSE | LXRX |
|---|---|---|
| Price | $9.49 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.55 |
| AVG Volume (30 Days) | 19.6K | ★ 2.9M |
| Earning Date | 10-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $1,305.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $9.05 | $1.10 |
| 52 Week High | $13.50 | $2.68 |
Technical Indicators
Market Signals| Indicator | ADSE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 22.39 | 27.74 |
| Support Level | N/A | $1.50 |
| Resistance Level | $12.07 | $1.81 |
| Average True Range (ATR) | 0.60 | 0.11 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 9.28 | 4.42 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.